228 related articles for article (PubMed ID: 29528698)
1. Opioids in Cardiovascular Disease: Therapeutic Options.
Rawal H; Patel BM
J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):279-291. PubMed ID: 29528698
[TBL] [Abstract][Full Text] [Related]
2. Non-analgesic effects of opioids: cardiovascular effects of opioids and their receptor systems.
Headrick JP; Pepe S; Peart JN
Curr Pharm Des; 2012; 18(37):6090-100. PubMed ID: 22747541
[TBL] [Abstract][Full Text] [Related]
3. Curcumin and cardiovascular diseases: Focus on cellular targets and cascades.
Pourbagher-Shahri AM; Farkhondeh T; Ashrafizadeh M; Talebi M; Samargahndian S
Biomed Pharmacother; 2021 Apr; 136():111214. PubMed ID: 33450488
[TBL] [Abstract][Full Text] [Related]
4. Activating transcription factor 3 in cardiovascular diseases: a potential therapeutic target.
Zhou H; Li N; Yuan Y; Jin YG; Guo H; Deng W; Tang QZ
Basic Res Cardiol; 2018 Aug; 113(5):37. PubMed ID: 30094473
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Safety of the Selective μ-Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation.
White WB; Kowey P; Diva U; Sostek M; Tummala R
J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):309-317. PubMed ID: 29504415
[TBL] [Abstract][Full Text] [Related]
6. Opioid Receptors.
Stein C
Annu Rev Med; 2016; 67():433-51. PubMed ID: 26332001
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of neuregulin-1 in cardiovascular disease.
Mendes-Ferreira P; De Keulenaer GW; Leite-Moreira AF; Brás-Silva C
Drug Discov Today; 2013 Sep; 18(17-18):836-42. PubMed ID: 23384772
[TBL] [Abstract][Full Text] [Related]
8. Emerging importance of chemokine receptor CXCR3 and its ligands in cardiovascular diseases.
Altara R; Manca M; Brandão RD; Zeidan A; Booz GW; Zouein FA
Clin Sci (Lond); 2016 Apr; 130(7):463-78. PubMed ID: 26888559
[TBL] [Abstract][Full Text] [Related]
9. The Future of Cardiovascular Therapeutics.
MacRae CA; Roden DM; Loscalzo J
Circulation; 2016 Jun; 133(25):2610-7. PubMed ID: 27324356
[No Abstract] [Full Text] [Related]
10. Relaxin' the Heart: A Novel Therapeutic Modality.
Raleigh JM; Toldo S; Das A; Abbate A; Salloum FN
J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):353-62. PubMed ID: 26589290
[TBL] [Abstract][Full Text] [Related]
11. Opioid receptors beyond pain control: The role in cancer pathology and the debated importance of their pharmacological modulation.
Carli M; Donnini S; Pellegrini C; Coppi E; Bocci G
Pharmacol Res; 2020 Sep; 159():104938. PubMed ID: 32504831
[TBL] [Abstract][Full Text] [Related]
12. Benefit-risk ratio of agonist-antagonist analgesics.
Lasagna L
Drug Alcohol Depend; 1987 Dec; 20(4):385-93. PubMed ID: 2894291
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic-sensitive pathways in personalized therapy of major cardiovascular diseases.
Schiano C; Benincasa G; Franzese M; Della Mura N; Pane K; Salvatore M; Napoli C
Pharmacol Ther; 2020 Jun; 210():107514. PubMed ID: 32105674
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular effects of sphingosine-1-phosphate (S1P).
Levkau B
Handb Exp Pharmacol; 2013; (216):147-70. PubMed ID: 23563656
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Effects of Urocortin-2: Pathophysiological Mechanisms and Therapeutic Potential.
Monteiro-Pinto C; Adão R; Leite-Moreira AF; Brás-Silva C
Cardiovasc Drugs Ther; 2019 Oct; 33(5):599-613. PubMed ID: 31512017
[TBL] [Abstract][Full Text] [Related]
16. Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia.
Hutchinson MR; Shavit Y; Grace PM; Rice KC; Maier SF; Watkins LR
Pharmacol Rev; 2011 Sep; 63(3):772-810. PubMed ID: 21752874
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of A2 adenosine receptor pharmacological regulators in the treatment of cardiovascular diseases, recent progress, and prospective.
Bahreyni A; Avan A; Shabani M; Ryzhikov M; Fiuji H; Soleimanpour S; Khazaei M; Hassanian SM
J Cell Physiol; 2019 Feb; 234(2):1295-1299. PubMed ID: 30146778
[TBL] [Abstract][Full Text] [Related]
18. Effects of geranylgeranylacetone upon cardiovascular diseases.
Zeng S; Wang H; Chen Z; Cao Q; Hu L; Wu Y
Cardiovasc Ther; 2018 Aug; 36(4):e12331. PubMed ID: 29656548
[TBL] [Abstract][Full Text] [Related]
19. The diverse molecular mechanisms responsible for the actions of opioids on the cardiovascular system.
Pugsley MK
Pharmacol Ther; 2002 Jan; 93(1):51-75. PubMed ID: 11916541
[TBL] [Abstract][Full Text] [Related]
20. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
